Fractionated local radiation therapy (RT) remains a primary treatment for many types of cancer. However for many large tumors, local failure is common. Strategies to successfully manipulate the tumor microenvironment to improve radiotherapy are under intensive investigation. Although ablative RT kill tumor cells directly we unexpectedly observed that initial tumor control following ablative RT is largely dependent on type I IFN and T cells but how irradiation induces IFN and how IFN helps T cells are less clear, RT-induced damage might also trigger tissue repair cascades, such as induction of TGFbeta, which induces M2-like macrophages which are associated with dampened RT initiated immunity potentially leading to tumor relapse. After initial screening with various cytokines and co-stimulatory molecules we find that local delivery of IL-21 after RT can improve microenvironment and controls tumor growth compared with either single treatment. We hypothesize that suppressive M2 macrophages post RT can be redirected to M1 macrophages to maximize anti-tumor immunity.
In aim 1, we will define how ablative RT both positively and negatively regulates immune responses. On one hand, we will study how local RT breaks tumor barriers and induces DNA-cGAS-STING for type I IFN pathway. On the other hand, we will study how RT-mediated tissue damage gradually induces suppressive M2 macrophages for tumor relapse.
In aim 2, we will study how IL-21 administration after RT can synergistically expand T cell responses and reduce RT resistance. We will study how RT-induced changes in microenvironment permits IL-21-Fc targeting to redirect suppressive M2 to supportive M1 macrophages that prevent relapse. We will determine whether such synergy depends on increased cytokines for macrophages and/or dendritic cells for cross-priming.
In aim 3, we will generate a Her2/neu-dependent sporadic tumor. We then study whether and how RT can synergize with immunotherapy in genetically induced spontaneous tumor model or distal metastasis. We can thus further evaluate whether local RT can enhance Ab-IL21-mediated immunity against sporadic tumor model and RT-resistant or metastatic tumor. Understanding of changing tumor microenvironment after RT will help us design better combination strategies to control treatment-induced resistance and establish long- lasting protection.

Public Health Relevance

Tumors form physical barriers and immunosuppressive environments. Our study has now shown that local radiation not only stimulates immunity for tumor regression but also regain immune suppression over time for relapse. We have now developed a novel, clinically relevant and highly effective combination treatment modality preventing relapse.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA134563-09
Application #
9237205
Study Section
Cancer Immunopathology and Immunotherapy Study Section (CII)
Program Officer
Ahmed, Mansoor M
Project Start
2008-07-01
Project End
2020-02-28
Budget Start
2017-03-01
Budget End
2018-02-28
Support Year
9
Fiscal Year
2017
Total Cost
$346,275
Indirect Cost
$132,525
Name
University of Texas Sw Medical Center Dallas
Department
Pathology
Type
Schools of Medicine
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Ren, Zhenhua; Guo, Jingya; Liao, Jing et al. (2017) CTLA-4 Limits Anti-CD20-Mediated Tumor Regression. Clin Cancer Res 23:193-203
Liao, Jing; Luan, Yan; Ren, Zhenhua et al. (2017) Converting Lymphoma Cells into Potent Antigen-Presenting Cells for Interferon-Induced Tumor Regression. Cancer Immunol Res 5:560-570
Michelle Xu, M; Pu, Y; Weichselbaum, R R et al. (2017) Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy. Oncogene 36:585-592
Xu, Meng Michelle; Pu, Yang; Han, Dali et al. (2017) Dendritic Cells but Not Macrophages Sense Tumor Mitochondrial DNA for Cross-priming through Signal Regulatory Protein ? Signaling. Immunity 47:363-373.e5
Zheng, Wenxin; Skowron, Kinga B; Namm, Jukes P et al. (2016) Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance. Oncotarget 7:43039-43051
Qiao, Jian; Liu, Zhida; Fu, Yang-Xin (2016) Adapting conventional cancer treatment for immunotherapy. J Mol Med (Berl) 94:489-95
Xu, Meng Michelle; Pu, Yang; Zhang, Yuan et al. (2016) The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies. Trends Immunol 37:141-153
Deng, Liufu; Liang, Hua; Fu, Sherry et al. (2016) From DNA Damage to Nucleic Acid Sensing: A Strategy to Enhance Radiation Therapy. Clin Cancer Res 22:20-5
Tang, Haidong; Wang, Yang; Chlewicki, Lukasz K et al. (2016) Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade. Cancer Cell 29:285-296
Ren, Zhenhua; Peng, Hua; Fu, Yang-Xin (2016) PD-1 Shapes B Cells as Evildoers in the Tumor Microenvironment. Cancer Discov 6:477-8

Showing the most recent 10 out of 40 publications